CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine MTD of CRTE7A2-01 TCR-T cell injection, as well as investigate RP2D.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Corregene Biotechnology Co., Ltd
• Treatments: Cyclophosphamide; Fludarabine; Interleukin-2

Criteria

Inclusion Criteria:

1. Age ≥18 years and ≤65 years.

2. Histologically-confirmed cervical cancer, anal cancer, head and neck cancers with confirmed HPV16 infection and HLA-A*02:01 allele

3. Failure on or intolerance to systemic therapy for unresectable advanced cancer.

4. ECOG performance status of 0-1.

5. Estimated life expectancy ≥ 3 months.

6. Patients must have at least one measurable lesion defined by RECIST 1.1.

7. Female patients of childbearing age must undergo a serum pregnancy test within 7 days prior to study treatment and the results must be negative, and are willing to use a very effective and reliable method of contraception from screening through 6 months after the last dose of study treatment.

8. The patient must be willing to sign the informed consent form and have a good anticipation of compliance with study procedure.

Exclusion Criteria：

1. The proportion of T cell immune-related gene deletion mutations>5%.

2. Patient received any genetically modified T cell therapy.

3. Patient who is being treated with T cell immunosuppressive agent （such as cyclophosphamide, FK506,tripterygium glycosides） or T cell immunoagonist.

4. Patients received chemotherapy, targeted therapy, immunotherapy, or other investigational agents within 2 weeks and received radiotherapy within 4 weeks before apheresis.

5. Patients with any organ dysfuntion as defined below:

• leukocytes<3.0 x 109/L

• absolute neutrophil count >1.5 x 109/L

• hemoglobin<90g/L

• platelets <100 x 1010/L

• lymphocytes<0.8 x 109/L

• percentage of lymphocytes<15%

• creatinine>1.5×ULN or creatinine clearance <50mL/min

• total bilirubin>3×ULN; ALT/AST>3×ULN (patients with liver metastasis,>5×ULN)

• INR>1.5×ULN; APTT>1.5×ULN

• SpO2≤90%

6. Patients with serious medical conditions, disorders, and / or comorbidities, including, but are not limited to: severe heart disease, cerebrovascular disease, epileptic seizures, uncontrolled diabetes (CTCAE 5.0: FBG ≥ 2 grade), active infection, active digestive tract Ulcer, gastrointestinal bleeding, intestinal obstruction, pulmonary fibrosis, renal failure, respiratory failure.

7. Patient with a severe cardiovascular disease with 6 months before screening, including, but are not limited to, myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, Heart failure NYHA grade Ⅲ or Ⅳ.

8. Left Ventricular Ejection Fractions (LVEF) <50%.

9. Patient with a known active brain metastases.

10. Patient with a known myelodysplastic syndrome (MDS) or lymphoma.

11. Patient with a known active autoimmune disease, including , but are not limited to, acquired or congenital immunodeficiency disease, allogeneic organ transplantation, autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel disease.

12. Patient with a known active Hepatitis B or Hepatitis C.

13. Patient with a history of Human Immunodeficiency Virus (HIV) .

14. Patient with a history of syphilis.

15. Pregnant or lactating women.

16. Patient with a known active mental and neurological diseases.

17. The principal investigator judged that it is not suitable to participate in this clinical study.